Influenza season has started in Europe
The season of active circulation of influenza viruses has started in Europe.
The season of active circulation of influenza viruses has started in Europe, concludes Flu News Europe, the joint weekly influenza bulletin by ECDC and WHO/Europe, covering data up to 4 January 2015 (Week 1).
Influenza activity building up
While many countries in Europe still report low levels of influenza activity, the proportion of influenza-positive sentinel specimens has been above 10% for the third consecutive week. According to reports by EU/EEA countries, 26% of all sentinel specimens tested during week 1 were positive for influenza. In week 1, an increasing number of EU/EEA countries – Iceland, Malta, the Netherlands, Portugal, Sweden, UK – report medium intensity of influenza activity.
A(H3N2) viruses predominant so far
Influenza A(H3N2) viruses have been the predominant viruses detected across all surveillance systems. As indicated in ECDC’s recent Rapid Risk Assessment on circulation of drifted influenza A(H3N2) viruses in the EU/EEA, in previous seasons, influenza A(H3N2) viruses have been associated with more severe disease than A(H1N1) and type B viruses. Most of the A(H3N2) viruses characterized genetically belong to genetic subgroups containing viruses that have drifted antigenically compared to the A(H3N2) virus in use for the 2014–2015 northern hemisphere influenza vaccine. Such a drift usually signals reduced vaccine effectiveness against that particular strain.
Influenza vaccination protects the vulnerable
Influenza vaccination, which provides protection against at least three strains of influenza each season, remains the most effective measure to prevent illness and possibly fatal outcomes also this season, despite the drift in one of the influenza strains. In the EU, up to 40 000 people die prematurely during an average influenza season. Protecting those who are at risk of severe outcomes of influenza remains the priority of vaccination programmes, particularly the elderly and those vulnerable due to pre-existing illnesses or risk factors.
Antivirals should be considered
Treatment and post-exposure prophylaxis with antivirals protects the elderly and people in risk groups against serious influenza illness. The circulating viruses analysed so far show susceptibility to the antiviral drugs oseltamivir and zanamivir. As advised in previous seasons and in particular in a potentially severe season predominated by the A(H3N2) virus, physicians should always consider treatment or post-exposure prophylaxis with antivirals when treating influenza-infected patients and exposed individuals in risk groups.
- Flu News Europe, joint weekly bulletin by ECDC and WHO/Europe
- Latest influenza maps and data in the EU/EEA
- Rapid Risk Assessment on circulation of drifted influenza A(H3N2) viruses in the EU/EEA
Influenza surveillance for the 2017-2018 season is starting
ECDC monitors and reports on influenza transmission and virus circulation in Europe on a weekly basis throughout the flu season, in collaboration with WHO Regional Office for Europe, in the report Flu News Europe.Read more
WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.Read more
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.Read more